News

A new study argues artificial intelligence will be a key tool in helping to evaluate the new barrage of new scientific research.

The 15 diagnostic guidelines weigh the currently accepted definition of coronavirus, and consider the prevalence of regional cases in at-risk patients.

Managing editor Kevin Kunzmann provides a summary of our daily COVID-19 coverage.

It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.

New data from a New York City-based hospital shows patients on blood thinners had a lower mortality risk due to COVID-19.

Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.

The data were released as part of the now-cancelled European Congress of Clinical Microbiology and Infectious Diseases.

Findings of BMC Public Health analysis suggest cost-cutting measures may delay diagnosis and treatment.

Until this week, French public health officials had believed coronavirus disease 2019 (COVID-19) had arrived in the country in January. A new study suggests it happened at least a month earlier.

An interview with the Rebiotix founder on the microbiota-based therapy and the newest preliminary pivotal phase 3 findings.

Device-related pressure injuries, moisture-associated skin damage, and skin tears were all common among Chinese clinicians treating the coronavirus.

A daily summary of our COVID-19 coverage.

A quartet of candidates will be simultaneously assessed in younger and older healthy adult patient groups in the phase 1/2 trials.

As children born in 2015-2016 with congenital Zika syndrome age, investigators are gradually able to assess neurodevelopmental outcomes.

The wearable technology is now authorized to monitor patients for changes in QT interval. Investigational drugs being administered to COVID-19 patients, such as chloroquine and hydroxychloroquine, can cause prolongation of QT intervals and life-threatening arrhythmias.

Michael B. Edmond, MD, MPH, MPA, MBA, explains his hypothesis that universally adopting face shields could help cut the transmissibility of COVID-19.

Virologists have taken marketed drugs from in-vitro screening for potential to repurpose for SARS-CoV-2 to in-vivo results in animal model.

Even after putting public health policies in place, the state reached 2600 nursing home cases before the end of April.

Flu burden for children can be reduced by improving adherence to a 2-dose series of flu vaccinations.

The attenuated virus in oral polio vaccines has developed the ability to evolve and spread to humans. Now, investigators have developed a new vaccine without the ability to make such changes.

Investigators in Italy found ceftolozane/tazobactam to be an effective treatment for some patients with severe ESBL-E infections.

A team of investigators lay out 3 scenarios for the global pandemic duration—based on previous pandemic learning and public health adherence.

Cornelius J. Clancy, MD, discusses navigating partial trial information and the need for coherent national coordination on the COVID-19 response.

Midway through the pandemic outbreak, investigators attempts to highlight some of the strongest candidates to fight the disease.

The test reports ≥99.8% specificity and 100% sensitivity at 14 days post-PCR confirmation, and could potentially better inform patient immunity and disease pathology.

Commentary outlines “best practices” for studies looking into possible treatments, vaccine.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of April 26, 2020.

We’ve compiled a list of notable recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Contagion Editor in Chief Jason Gallagher, PharmD, discusses the new authorization for the controversial antiviral therapy.

The decision comes shortly after conflicting human trial results assessing the intravenous antiviral drug.